Browse CCR9

Summary
SymbolCCR9
Namechemokine (C-C motif) receptor 9
Aliases GPR-9-6; CDw199; GPR28; CC-CKR-9; G protein-coupled receptor 28; CD antigen CDw199; G-protein coupled recept ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Multi-pass membrane protein
Domain PF00001 7 transmembrane receptor (rhodopsin family)
Function

Receptor for chemokine SCYA25/TECK. Subsequently transduces a signal by increasing the intracellular calcium ions level. ; FUNCTION: (Microbial infection) Alternative coreceptor with CD4 for HIV-1 infection.

> Gene Ontology
 
Biological Process GO:0002304 gamma-delta intraepithelial T cell differentiation
GO:0002305 CD8-positive, gamma-delta intraepithelial T cell differentiation
GO:0002521 leukocyte differentiation
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006968 cellular defense response
GO:0007159 leukocyte cell-cell adhesion
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0030098 lymphocyte differentiation
GO:0030217 T cell differentiation
GO:0042110 T cell activation
GO:0042492 gamma-delta T cell differentiation
GO:0046629 gamma-delta T cell activation
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0055074 calcium ion homeostasis
GO:0070098 chemokine-mediated signaling pathway
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
Molecular Function GO:0001637 G-protein coupled chemoattractant receptor activity
GO:0001653 peptide receptor activity
GO:0004896 cytokine receptor activity
GO:0004950 chemokine receptor activity
GO:0008528 G-protein coupled peptide receptor activity
GO:0016493 C-C chemokine receptor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
hsa04672 Intestinal immune network for IgA production
Reactome R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolCCR9
Namechemokine (C-C motif) receptor 9
Aliases GPR-9-6; CDw199; GPR28; CC-CKR-9; G protein-coupled receptor 28; CD antigen CDw199; G-protein coupled recept ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CCR9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CCR9 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25691366Breast CarcinomaInhibit immunity (T cell function)Unlike PDL1, which inhibits TCR signaling, CCR9 regulates STAT signaling in T cells, resulting in reduced T-helper-1 cytokine secretion and reduced cytotoxic capacity. Moreover, inhibition of CCR9 expression on tumor cells facilitated immunotherapy of human tumors by tumor-specific T cells in vivo.
Summary
SymbolCCR9
Namechemokine (C-C motif) receptor 9
Aliases GPR-9-6; CDw199; GPR28; CC-CKR-9; G protein-coupled receptor 28; CD antigen CDw199; G-protein coupled recept ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CCR9 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA Resistant to T cell-mediated killing
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCCR9
Namechemokine (C-C motif) receptor 9
Aliases GPR-9-6; CDw199; GPR28; CC-CKR-9; G protein-coupled receptor 28; CD antigen CDw199; G-protein coupled recept ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CCR9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.2810.148
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.9480.134
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.4370.777
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.1860.0633
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15112.1660.138
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0810.958
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1080.793
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1920.75
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0350.856
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CCR9 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382707.4-7.40.169
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCCR9
Namechemokine (C-C motif) receptor 9
Aliases GPR-9-6; CDw199; GPR28; CC-CKR-9; G protein-coupled receptor 28; CD antigen CDw199; G-protein coupled recept ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCR9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCCR9
Namechemokine (C-C motif) receptor 9
Aliases GPR-9-6; CDw199; GPR28; CC-CKR-9; G protein-coupled receptor 28; CD antigen CDw199; G-protein coupled recept ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCR9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCR9.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCCR9
Namechemokine (C-C motif) receptor 9
Aliases GPR-9-6; CDw199; GPR28; CC-CKR-9; G protein-coupled receptor 28; CD antigen CDw199; G-protein coupled recept ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCR9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCCR9
Namechemokine (C-C motif) receptor 9
Aliases GPR-9-6; CDw199; GPR28; CC-CKR-9; G protein-coupled receptor 28; CD antigen CDw199; G-protein coupled recept ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CCR9 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCCR9
Namechemokine (C-C motif) receptor 9
Aliases GPR-9-6; CDw199; GPR28; CC-CKR-9; G protein-coupled receptor 28; CD antigen CDw199; G-protein coupled recept ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CCR9 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCCR9
Namechemokine (C-C motif) receptor 9
Aliases GPR-9-6; CDw199; GPR28; CC-CKR-9; G protein-coupled receptor 28; CD antigen CDw199; G-protein coupled recept ......
Chromosomal Location3p21.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CCR9 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CCR9.
ID Name Drug Type Targets #Targets
DB05005CCX282Small MoleculeCCR91